"Q. I just had a quick question on 2021 and the impact of taking on tislelizumab. I was just wondering if you could give us a sense of the order of magnitude of the incremental development costs that you'll be taking on with this asset. And is that mostly coming from R&D and the initiation of these combination trials?"